Repair of the dura mater with processed collagen devices

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 83, Issue 2, 2007, Pages 580-588

  Zerris, Vasilios A ^a   James, Kenneth S ^b   Roberts, Julie B ^b   Bell, Eugene ^b   Heilman, Carl B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TEI Biosciences   (United States)

Author keywords

Acellular dermal matrix; Collagen; Dural graft substitute; Duraplasty; Remodeling; Xenograft

Indexed keywords

BRAIN; COLLAGEN; DIFFERENTIAL SCANNING CALORIMETRY; GRAFTS; PATIENT TREATMENT; STIFFNESS;

ACELLULAR DERMAL MATRIX; DURAL GRAFT SUBSTITUTES; DURAPLASTY; XENOGRAFT;

BIOLOGICAL MEMBRANES;

COLLAGEN;

ANIMAL EXPERIMENT; ARTICLE; CROSS LINKING; DENATURATION; DIFFERENTIAL SCANNING CALORIMETRY; DOG; DURA MATER; FEMALE; NONHUMAN; POROSITY; RIGIDITY; SCANNING ELECTRON MICROSCOPY; SUTURE; TENSILE STRENGTH; THICKNESS; XENOGRAFT; YOUNG MODULUS;

ANIMALS; BIOCOMPATIBLE MATERIALS; CATS; CATTLE; COLLAGEN; DURA MATER; FEMALE; HEAT; MICROSCOPY, ELECTRON, SCANNING; TENSILE STRENGTH;

EID: 35548961934     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.30831     Document Type: Article

References (29)

1. Maurer PK, JV McDonald JV. Vicryl (polyglactin 910) mesh as a dural substitute. J Neurosurg 1985;63:448-452.
2. Nussbaum CE, Maurer PK, McDonald JV. Vicryl (polyglactin 910) mesh as a dural substitute in the presence of pia arachnoid injury. J Neurosurg 1989;71:124-127.
3. Parizek J, Mericka P, Spacek J, Nemecek S, Elias P, Sercl M. Xenogeneic pericardium as a dural substitute in reconstruction of suboccipital dura mater in children. J Neurosurg 1989;70:905-909.
4. Warren WL, Medary MB, Dureza CD, Bellotte JB, Flannagan PP, Oh MY, Fukushima T. Dural repair using acellular human dermis: Experience with 200 cases: Technique assessment. Neurosurgery 2000;46:1391-1396.
5. Yamada K, Miyamoto S, Nagata I, Kikuchi H, Ikada Y, Iwata H, Yamamoto K. Development of a dural substitute from synthetic bioabsorbable polymers. J Neurosurg 1997;86:1012-1017.
6. Yamada K, Miyamoto S, Takayama M, Nagata I, Hashimoto N, Ikada Y, Kikuchi H. Clinical application of a new bioabsorbable artificial dura mater. J Neurosurg 2002;96:731-735.
7. Mello LR, Feltrin LT, Fontes Neto PT, Ferraz FA. Duraplasty with biosynthetic cellulose: An experimental study. J Neurosurg 1997;86:143-150.
8. Van Noort R, Black MM, Martin TR, Meanley S. A study of the uniaxial mechanical properties of human dura mater preserved in glycerol. Biomaterials 1981;2:41-45.
9. McGarvey KA, Lee JM, Boughner DR. Mechanical suitability of glycerol-preserved human dura mater for construction of prosthetic valves. Biomaterials 1984;5:109-117.
10. Wolfinbarger L, Zhang Y, Adam B, Homsi D, Gates K, Milbourn V. Biomechanical study of human allograft dura-mater tissues. Transfusion 1993;7:616.
11. Sacks MS, Jimenez H, Otano-Lata SE, Malinin TI. Local mechanical anisotropy in human cranial dura mater allografts. J Biomech Eng 1998;4:541-544.
12. Sung HW, Chang Y, Chiu CT, Chen CN, Liang HC. Crosslinking characteristics and mechanical properties of a bovine pericardium fixed with a naturally occurring crosslinking agent. J Biomed Mater Res 1999;47:116-126.
13. Sung HW, Liang IL, Chen CN, Huang RN, Liang HF. Stability of a biological tissue fixed with a naturally occurring crosslinking agent (genipin). J Biomed Mater Res 2001;55:538-546.
14. Sung HW, Huang RN, Huang LL, Tsai CC, Chiu CT. Feasibility of a natural crosslinking reagent for biological tissue fixation. J Biomed Mater Res 1998;42:560-567.
15. Huang LL, Sung HW, Tsai CC, Huang DM. Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent. J Biomed Mater Res 1998;42:568-576.
16. Berjano R, Vinas F, Dujovny M. A review of dural substitutes used in neurosurgery. Crit Rev Neurosurg 1999;9:217-222.
17. Constantino P, Wolpoe M. Human dural replacement with acellular dermis: Clinical results with a review of literature. Head Neck 2000;22:765-771.
18. Finster H. Ueber den plastischen duraerstz und dessen bedeutung fur die operative behandlung der Jackson-Epilepsie. Beitr Klin Chir 1910;66:193-210.
19. Abbott I, Dupree E. Clinical results of lyophilized human cadaver dura transplantation. J Neurosurg 1971;34:770-773.
20. Parizek J, Mericka P, Husek Z, Suba P, Spacek J, Nemecek S, Nemeckova J, Sercl M, Elias P. Detailed evaluation of 2959 allogeneic and xenogeneic dense connective tissue grafts (fascia lata, pericardium, and dura mater) used in the course of 20 years for duraplasty in neurosurgery. Acta Neurochirurgica 1997;139:827-838.
21. Lang CJ, Schuler P, Engelhardt A, Spring A, Brown P. Probable Creutzfeldt-Jakob disease after a cadaveric dural graft. Eur J Epidemiol 1995;11:79-81.
22. Liscic RM, Brinar V, Miklic P, Barsic B, Himbele J. Creutzfeldt-Jakob disease in a patient with a lyophilized dura mater graft. Acta Medica Croatica 1999;53:93-96.
23. Martinez-Lage JF, Sola J, Poza M, Esteban JA. Pediatric Creutzfeldt-Jakob disease: Probable transmission by a dural graft. Childs Nerv Syst 1993;9:239-242.
24. Miyashita K, Inuzuka T, Kondo H, Saito Y, Fujita N, Matsubara N, Tanaka R, Hinokuma K, Ikuta F, Miyatake T. Creutzfeldt-Jakob disease in a patient with a cadaveric dural graft. Neurology 1991;41:940-941.
25. Takashima S, Tateishi J, Taguchi Y, Inoue H. Creutzfeldt-Jakob disease with florid plaques after cadaveric dural graft in a Japanese woman. Lancet 1997;350:865-866.
26. Takayama S, Hatsuda N, Matsumura K, Nakasu S, Handa J. [Creutzfeldt-Jakob disease transmitted by cadaveric dural graft: A case report]. No Shinkei Geka Neurol Surg 1993;21:167-170.
27. FDA. Action plan transmissible spongioform encephalopathies include BSE and chronic wasting disease. Rockville, MD; 2001.
28. WHO. Report of a WHO (World Health Organization) consultation on medicinal and other products in relation to human and animal transmissible spongioform encephalopathies-with the participation of the Office International des Epizooties (OIE). Geneva, Switzerland; 1997, pp 24-26.
29. WHO. WHO infection control guidlines for transmissible spongioform encephalopathies. Report of a WHO consultation, Geneva, Switzerland; 1999, pp 23-26.